{
    "2018-02-27": [
        [
            {
                "time": "",
                "original_text": "泰格医药：2017年净利润同比增116.91%（快报）",
                "features": {
                    "keywords": [
                        "泰格医药",
                        "净利润",
                        "同比增长",
                        "116.91%",
                        "快报"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "泰格医药股票怎么样：业绩高速增长，受益于创新药行业发展",
                "features": {
                    "keywords": [
                        "泰格医药",
                        "业绩",
                        "高速增长",
                        "创新药",
                        "行业发展"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "【川财研究*医药生物】泰格医药（300347）：2017业绩高增长，长期坚定看好",
                "features": {
                    "keywords": [
                        "川财研究",
                        "医药生物",
                        "泰格医药",
                        "2017",
                        "业绩高增长",
                        "长期看好"
                    ],
                    "sentiment_score": 0.95,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "泰格医药:年报业绩符合预期,鼓励创新药和仿制药一致性评价政策双受益",
                "features": {
                    "keywords": [
                        "泰格医药",
                        "年报",
                        "业绩",
                        "符合预期",
                        "创新药",
                        "仿制药",
                        "一致性评价",
                        "政策",
                        "双受益"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}